1. Home
  2. JBLU vs ANAB Comparison

JBLU vs ANAB Comparison

Compare JBLU & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JetBlue Airways Corporation

JBLU

JetBlue Airways Corporation

HOLD

Current Price

$4.12

Market Cap

1.5B

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$63.52

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBLU
ANAB
Founded
1998
2005
Country
United States
United States
Employees
22087
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2002
2015

Fundamental Metrics

Financial Performance
Metric
JBLU
ANAB
Price
$4.12
$63.52
Analyst Decision
Sell
Strong Buy
Analyst Count
12
10
Target Price
$5.02
$70.60
AVG Volume (30 Days)
16.3M
439.6K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
27.83
91.02
EPS
N/A
N/A
Revenue
$9,062,000,000.00
$234,603,000.00
Revenue This Year
$10.08
N/A
Revenue Next Year
$7.54
$43.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
157.01
52 Week Low
$3.34
$15.32
52 Week High
$6.46
$66.66

Technical Indicators

Market Signals
Indicator
JBLU
ANAB
Relative Strength Index (RSI) 28.67 66.99
Support Level $4.04 $43.67
Resistance Level $4.72 N/A
Average True Range (ATR) 0.28 3.71
MACD -0.16 0.75
Stochastic Oscillator 1.63 86.73

Price Performance

Historical Comparison
JBLU
ANAB

About JBLU JetBlue Airways Corporation

JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: